Why the study?
Does a single oral dose of cisapride increase plasma aldosterone levels in patients with idiopathic hyperaldosteronism?
Does a single oral dose of cisapride increase plasma aldosterone levels in patients with idiopathic hyperaldosteronism?
The study demonstrates that 5-HT4 receptor agonists stimulate aldosterone secretion in idiopathic hyperaldosteronism, suggesting that 5-HT4 receptor antagonists may represent a novel therapeutic approach for primary hyperaldosteronism.
Answers are grounded in this paper and cite their sources.
Cisapride raises aldosterone in idiopathic hyperaldosteronism; extends rationale for 5-HT4 antagonists as targeted therapy in primary aldosteronism.
Serotonin (5-HT) stimulates aldosterone secretion in man through 5-HT4 receptors positively coupled to adenylyl cyclase. In particular, it has been shown that oral administration of a single dose of the 5-HT4 receptor agonist cisapride induces a significant increase in plasma aldosterone levels (PAL) in healthy volunteers. Idiopathic hyperaldosteronism (IH) is a rare disorder characterized by hypertension, hypokalemia and bilateral adrenal hypersecretion of aldosterone. In patients with IH, administration of the 5-HT precursor 5-hydroxytryptophan (5-HTP) is followed by a significant increase in PAL. 5-HTP-induced aldosterone secretion has been attributed to the activation of central serotonergic pathways. The aim of the present study was to evaluate the effect of the oral administration of a single dose of cisapride (10 mg) on aldosterone secretion in 15 patients with IH, in a simple blind fashion versus placebo. Cisapride induced a significant increase in PAL but did not affect renin, cortisol and potassium levels. The present study demonstrates that 5-HT4 receptor agonists are able to stimulate aldosterone secretion in patients with IH. These data also indicate that hyperplastic glomerulosa tissue, like normal glomerulosa cells, expresses a functional 5-HT4 receptor. Therefore, 5-HT4 receptor antagonists may represent a new approach in the treatment of primary hyperaldosteronism.
No takes yet. Share an insight, caveat, or question.
Lefèbvre et al. (2000) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: